How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

The maker of Claude wants AI labs, including itself, to prepare for a coordinated slowdown if models begin building their own successors ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Know how to get the most out of your predictive tools. by Michael Luca, Jon Kleinberg and Sendhil Mullainathan Most managers’ jobs involve making predictions. When HR specialists decide whom to hire, ...

Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...

View post: Hobby Lobby's $17 Large Acacia Wood Serving Board Is the Perfect Summer Hosting Find View post: We Asked 3 Chefs the Best Thing To Make With Canned Chicken, and They All Said the Same Thing ...

Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.